Stada and Xbrane Add Two To Biosimilar Development Alliance

Stada and Xbrane have expanded their biosimilar development alliance by adding the Swedish firm’s certolizumab and nivolumab pre-clinical programs to the partnership.

Sum
Stada and Xbrane have added certolizumab and nivolumab to their existing biosimilar alliance covering ranibizumab • Source: Shutterstock

Stada Arzneimittel and Xbrane Biopharma have expanded their strategic biosimilar development partnership to cover pre-clinical programs for certolizumab pegol and nivolumab, as well as potentially other early-stage candidates.

“Xbrane and Stada will focus on biosimilars to originator products with patent expiration 2025-2030 and have identified two programs in...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business